Additions to the clinical trials list

[vc_row][vc_column][vc_empty_space][vc_column_text]FOR PATIENTS THAT HAVE NOT HAD ANY PREVIOUS DRUG TREATMENT

• A Study of Belzutifan + Pembrolizumab versus Pembrolizumab Alone for Patients with Advanced Kidney Cancer

[/vc_column_text][vc_column_text]

• A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer

[/vc_column_text][vc_empty_space][vc_column_text]FOR PATIENT WHO HAVE HAD PREVIOUS DRUG TREATMENT

• A Study of Belzutifan + Lenvatinib versus Cabozantinib Alone for Patients with Advanced Kidney Cancer

[/vc_column_text][vc_column_text]

• A Study of Different Immune and Targeted Therapies for 2nd Line (or higher) Treatment of Kidney Cancer (Substudy 03B)

[/vc_column_text][vc_empty_space][/vc_column][/vc_row]